The results of three recent, practice-changing Phase III clinical trials were presented for the first time in North America at the NANETS symposium which included: (1) TELESTAR (randomized Phase III trial of telotristat vs. placebo in patients with carcinoid syndrome), (2) NETTER-1 (randomized Phase III trial of 177-Lu-DOTATATE vs. high dose octreotide in patients with progressive midgut NETs), and (3) RADIANT-4 (randomized Phase III trial of everolimus vs. placebo in advanced non-functional GI and lung NETs). NANETS will continue to keep you informed on the progress of the regulatory submissions for all three of these treatments.

I am pleased to announce the election results, and to both congratulate and extend a warm welcome to the new members of our Board of Directors, Advisory Board, and Nominating Committee.

NANETS congratulates Bryson William Katona as the 2015 Young Investigator grant recipient for his work on ER stress and the unfolded protein response in neuroendocrine tumor proliferation.